Plus Therapeutics
PSTV3.6303.46% ( -0.130 )
Plus Therapeutics (PSTV)
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with...
- Open
- 3.770
- High
- 3.770
- Low
- 3.550
- Prev. Close
- 3.760
- Volume
- 94.05K
- Turnover
- 339.64K
- Avg Price
- 3.611
- Bid/Ask Ratio
- --
- Amplitude
- 5.85%
- 52wk High
- 23.425
- Volume Ratio
- 1.42
- Turnover Ratio
- 1.48%
Plus Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 1, 2026Price forecast
$36.00891.74%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 06:30 AM
Plus Therapeutics signs Medical Mutual coverage deal for CNSide CSF tumor cell assay in Ohio, Kentucky
- rttnews · Jul 20 at 08:48 AM
A New CNS Cancer Treatment Playbook In The Making?
- PUBT · Jul 16 at 06:31 AM
Plus Therapeutics partners with Genomic Testing Cooperative to add NGS to CNSide CSF assay platform
- Global Report · Jul 14 at 06:47 AM
From Buybacks to Insider Buying: U.S. Mid-Caps Signal Capital Shift
- Unusual Whales · Jul 14 at 06:31 AM
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
- PUBT · Jul 14 at 06:31 AM
Plus Therapeutics flags availability of CNS cancers guidelines update release
